---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-032164"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:25:28.466963+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q1 2026: Net sales $759.9M (+27% YoY); raises FY non-GAAP EPS guidance to $4.70-$4.80

## Summary
- GAAP diluted EPS $0.90 (+66.6% YoY); non-GAAP diluted EPS $1.12 (+64.7% YoY).
- Worldwide net sales $759.9M, up 27% as-reported; base business (ex-Nevro) up 13.2%.
- FY2026 revenue guidance reaffirmed at $3.18B–$3.22B; non-GAAP EPS guidance raised to $4.70–$4.80 from $4.40–$4.50.
- U.S. net sales +25% YoY; international +35.6% as-reported (+27.8% constant currency).
- Operating margin expanded on manufacturing initiatives and operating leverage.

## SEC filing metadata
- accession: 0001628280-26-032164
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000162828026032164/0001628280-26-032164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000162828026032164/gmed-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-032164
- JSON: https://secwatch.observer/filing/0001628280-26-032164.json
- Plain text: https://secwatch.observer/filing/0001628280-26-032164.txt

## Source-grounded claims
- claim_id: 0dad7634d59c90b9b8966500bf6bf0bea3209ce6
  claim: GLOBUS MEDICAL INC reported the first quarter ended March 31, 2026 results: revenue $759.9 million, net income $124.3 million, EPS $0.90.
  evidence_excerpt: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: • Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis. • Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis. • GAAP net income for the quarter was $124.3 million. • GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000162828026032164/0001628280-26-032164-index.htm
- claim_id: 9def495eb37802f000b12bdf6a13f6ddfc08f0bb
  claim: GLOBUS MEDICAL INC reported full-year 2026 results: revenue $3.18 billion to $3.22 billion, EPS $4.70 to $4.80. Guidance raised.
  evidence_excerpt: The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000162828026032164/0001628280-26-032164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.